WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H563143
CAS#: 1308631-40-4
Description: NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity.
Hodoodo Cat#: H563143
Name: NDMC101
CAS#: 1308631-40-4
Chemical Formula: C13H9ClFNO2
Exact Mass: 265.03
Molecular Weight: 265.668
Elemental Analysis: C, 58.77; H, 3.41; Cl, 13.34; F, 7.15; N, 5.27; O, 12.04
Synonym: NDMC101; NDMC-101; NDMC 101; HS-Cm; HS Cm; HSCm;
IUPAC/Chemical Name: N-(4-Chloro-2-fluorophenyl)-2-hydroxybenzamide
InChi Key: NUQWCDAXACRITO-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H9ClFNO2/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17/h1-7,17H,(H,16,18)
SMILES Code: O=C(NC1=CC=C(Cl)C=C1F)C2=CC=CC=C2O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 265.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lee CC, Liu FL, Chen CL, Chen TC, Liu FC, Ahmed Ali AA, Chang DM, Huang HS. Novel inhibitors of RANKL-induced osteoclastogenesis: Design, synthesis, and biological evaluation of 6-(2,4-difluorophenyl)-3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-diones. Bioorg Med Chem. 2015 Aug 1;23(15):4522-32. doi: 10.1016/j.bmc.2015.06.007. Epub 2015 Jun 10. PubMed PMID: 26081760.
2: Lee CC, Liu FL, Chen CL, Chen TC, Chang DM, Huang HS. Discovery of 5-(2',4'-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis. Eur J Med Chem. 2015 Jun 15;98:115-26. doi: 10.1016/j.ejmech.2015.05.015. Epub 2015 May 15. PubMed PMID: 26005025.
3: Liou JT, Huang HS, Chiang ML, Lin CS, Yang SP, Ho LJ, Lai JH. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32. PubMed PMID: 24491838.
4: Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. doi: 10.1007/s10875-012-9660-9. Epub 2012 Feb 23. PubMed PMID: 22396044.
